Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation.
作者信息
Fortún Abete Jesús, Martín-Dávila Pilar, Moreno S, Quijano Yolanda, de Vicente Emilio, Pou Leonor
出版信息
Antimicrob Agents Chemother. 2004 Jul;48(7):2782-3. doi: 10.1128/AAC.48.7.2782-2783.2004.
Abstract
摘要
相似文献
1
Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation.口服缬更昔洛韦与静脉注射更昔洛韦在一名接受小肠移植的成年患者中预防巨细胞病毒疾病的药代动力学。
Antimicrob Agents Chemother. 2004 Jul;48(7):2782-3. doi: 10.1128/AAC.48.7.2782-2783.2004.
2
Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.口服缬更昔洛韦溶液和静脉注射更昔洛韦在儿童肾移植和肝移植受者中的药代动力学
Transpl Infect Dis. 2010 Jun;12(3):195-203. doi: 10.1111/j.1399-3062.2009.00478.x. Epub 2009 Dec 4.
3
Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.在HIV和CMV血清反应阳性志愿者中多次口服缬更昔洛韦后缬更昔洛韦和更昔洛韦的药代动力学。
Clin Pharmacokinet. 1999 Aug;37(2):167-76. doi: 10.2165/00003088-199937020-00005.
4
Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.评价肺移植受者更昔洛韦的药代动力学。
J Heart Lung Transplant. 2012 Feb;31(2):159-66. doi: 10.1016/j.healun.2011.11.016.
5
Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl.儿童口服缬更昔洛韦：一名6岁女孩的单剂量药代动力学
Pediatr Infect Dis J. 2004 Mar;23(3):263-6. doi: 10.1097/01.inf.0000116760.16582.a9.
6
Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.静脉注射更昔洛韦和口服液体缬更昔洛韦制剂后新生儿更昔洛韦的群体药代动力学。
Clin Pharmacol Ther. 2007 Jun;81(6):867-72. doi: 10.1038/sj.clpt.6100150. Epub 2007 Mar 28.
7
Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.缬更昔洛韦用于免疫功能低下宿主巨细胞病毒病的预防和治疗。
Expert Rev Anti Infect Ther. 2004 Feb;2(1):27-41. doi: 10.1586/14787210.2.1.27.
8
9
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.更昔洛韦在实体器官移植受者口服给药后以及从前体药物缬更昔洛韦给药后的药代动力学特征。
Clin Pharmacokinet. 2005;44(5):495-507. doi: 10.2165/00003088-200544050-00003.
10
Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract.在患有胃肠道移植物抗宿主病的异基因干细胞移植患者中，口服缬更昔洛韦与静脉注射更昔洛韦后更昔洛韦的药代动力学。
Biol Blood Marrow Transplant. 2006 Jun;12(6):635-40. doi: 10.1016/j.bbmt.2005.12.038.
引用本文的文献
1
HCMV Antivirals and Strategies to Target the Latent Reservoir.CMV 抗病毒药物和针对潜伏库的策略。
Viruses. 2021 May 1;13(5):817. doi: 10.3390/v13050817.
2
Management of cytomegalovirus corneal endotheliitis.巨细胞病毒性角膜内皮炎的管理
Eye Vis (Lond). 2021 Jan 14;8(1):3. doi: 10.1186/s40662-020-00226-y.
3
Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery.胃旁路手术后多形性胶质母细胞瘤患者中替莫唑胺的处置情况。
J Neurooncol. 2009 Jun;93(2):279-83. doi: 10.1007/s11060-008-9773-4. Epub 2009 Jan 6.
本文引用的文献
1
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients.缬更昔洛韦可提高肝移植受者对更昔洛韦的口服吸收。
Antimicrob Agents Chemother. 2000 Oct;44(10):2811-5. doi: 10.1128/AAC.44.10.2811-2815.2000.
2
Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.缬更昔洛韦在HIV和CMV血清学阳性受试者中的单剂量药代动力学。
J Clin Pharmacol. 1999 Aug;39(8):800-4. doi: 10.1177/00912709922008452.
3
Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation.肠道移植后巨细胞病毒病发生的发病率及相关危险因素。
Transplantation. 1995 Apr 15;59(7):1010-4. doi: 10.1097/00007890-199504150-00016.
Zotero 插件